Measuring Oncological Value of Exercise and Statin (MOVES)
Key facts
- Where
- Tampere, FinnországSee the site
- Phase
- 3. fázis
Where in Finnország
- Pirkanmaan hyvinvointialueTampere, FinnországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pirkanmaan hyvinvointialue
- Trial code
- EU 2024-515109-24-00
- Record updated
- 2026. május 21.
- Original description
1) Whether supervised group exercise with aerobic and resistance training during anticancer therapy improves the efficacy of anticancer therapy in advanced breast, renal, ovarian, and prostate cancer compared with self-administered exercise and whether the use of atorvastatin combined with supervised group exercise further improves the response to cancer treatment.Read full original descriptionShow less
1) Whether supervised group exercise with aerobic and resistance training during anticancer therapy improves the efficacy of anticancer therapy in advanced breast, renal, ovarian, and prostate cancer compared with self-administered exercise and whether the use of atorvastatin combined with supervised group exercise further improves the response to cancer treatment.
Inclusion: Patients with histologically and imaging confirmed metastatic prostate, breast, ovarian or renal cancer for which 1st line anticancer therapy is being initiated. 2) The patient consents to the study and signs a written informed consent. 3) Women (breast, ovarian and renal cancer) and men (prostate and renal cancer) of legal age (18 years =>) are recruited. 4) Women will use a reliable method of contraception during the trial.
Exclusion: All patients: 1. High fracture risk 2. Unable to exercise and/or unable to receive anticancer therapy 3. Psychologically uncooperative 4. Severe liver or kidney failure 5. Special category of subjects under the Medical Research Act (1999/488) (e.g. minors and pregnant or breastfeeding women). In addition to excl. criteria for patients who were not on statin medication at the start of the study: Active use of cholesterol-lowering drugs, A history of serious side effects from cholesterol-lowering drugs and Continued use of drugs that interact with atorvastatin during the period of the study.